Compare Medtronic PLC (MDT) vs Riot Platforms Inc (RIOT) Price & Performance

Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.

The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.

RIOT trades at $19.90, up 8.98% today but facing bearish technical signals with the stock trading below key resistance levels. The company reported a net loss of $663.18 million in 2025 with negative profit margins, though revenue reached $647.44 million. Analyst consensus remains overwhelmingly bullish with 94% buy ratings and a $27.86 price target, representing 40% upside potential from current levels.

While Wall Street maintains strong buy recommendations, RIOT faces significant fundamental challenges with persistent losses and negative cash flow from operations. The stock's investment case hinges on successful execution of the company's strategic pivot toward high-performance computing and data center expansion, though operational losses and competitive pressures present substantial risks to shareholder value.